Press "Enter" to skip to content

Amgen’s AMG420 shows responses in myeloma trial, gets FDA fast track

Amgen also said that AMG420, which targets a protein linked to multiple myeloma known as BCMA, has been given fast track status by the U.S. Food and Drug Administration.

Original source:

Also Read:   Hope of Covid-19 vaccine deployment in UK by New Year: Report